There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 4 | 58 | 2161.7 |
| 1 | 16 | 2161.6 |
| 3 | 48 | 2161.5 |
| 3 | 46 | 2161.4 |
| 3 | 65 | 2161.3 |
| Ask | Qty | Orders |
|---|---|---|
| 2162.2 | 3 | 43 |
| 2162.3 | 1 | 41 |
| 2162.4 | 1 | 40 |
| 2163 | 2 | 29 |
| 2163.2 | 1 | 29 |
Our researchers has found no immediate positive insights for this stock. We'll update this space as soon as we find something.
Founded in 1968 by Dr. Desh Bandhu Gupta, Lupin Limited is a Mumbai‑headquartered, innovation‑led transnational pharmaceutical company. Incorporated in 1983, the company develops, manufactures and markets a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) . Lupin has significant presence across Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro‑Intestinal, Anti‑Infectives and Nonsteroidal Anti‑Inflammatory Drug therapies, and is a global leader in Anti‑TB and Cephalosporins . Its products are distributed in over 100 markets, with strong presence across North America, EMEA, LATAM, APAC and India; operations span 112 countries as per the Business Responsibility and Sustainability Report . Manufacturing locations are spread across India, USA, Mexico and Brazil, with 15 manufacturing sites and seven research centres supporting global supply and innovation fileciteturn5 .
As on March 31, 2025, Lupin had 32 subsidiaries worldwide (do not list names) and one joint venture, reflecting its diversified operating footprint and corporate structure . Key milestones in the latest year included 41 product filings, 52 approvals and 87 patents secured, underscoring the company’s focus on complex generics and specialty portfolios across major markets .
– North America contributed 36 Per cent to revenues in FY25, affirming Lupin’s scale in the U.S. generics market .
– India contributed 34 Per cent to global turnover in FY25 .
– Other Developed Markets (Europe and Australia) contributed 11 Per cent of global revenues .
– Emerging Markets contributed 11 Per cent of global revenues .
– Domestic vs. International: On a standalone basis, exports comprised 53.9 Per cent of total sales in FY25 .
– Manju D. Gupta – Chairperson
– Vinita Gupta – Chief Executive Officer
– Nilesh D. Gupta – Managing Director
– Ramesh Swaminathan – Executive Director, Global CFO, Head of IT and API Plus SBU
– Amit Kumar Gupta – Company Secretary
– Portfolio and market expansion: Lupin acquired Eli Lilly’s Huminsulin and three diabetes products from Boehringer Ingelheim in India; it also acquired two specialty brands from Sanofi (Aarane in Germany and Nalcrom in Canada and the Netherlands) .
– Biologics progress: The company launched its first biosimilar, Rymti, in Canada and filed for Ranibizumab in the EU .
– Subsidiary additions: Lupin incorporated Lupin Lanka (Private) Limited in Sri Lanka and Lupin NZ Limited in New Zealand, expanding its presence in South Asia and Oceania .
– Pipeline momentum: In FY25, Lupin filed 41 products and received 52 approvals; 87 patents were secured, highlighting continued R&D intensity across inhalation, injectables, ophthalmic and oral segments .
– Regional performance highlights: North America sales grew 15.9 Per cent; Other Developed Markets rose 23.4 Per cent; Emerging Markets increased 6.8 Per cent, supported by differentiated portfolios and supply chain agility .
LUPIN LIMITED has delivered a return of -5.98% over the last 3 months. The stock was trading at ₹2,267.70 on 05 Jun 2026 and is currently at ₹2,110.00 as of 05 Sep 2026, reflecting a Loss of ₹157.70 per share over this period.
The intraday high for LUPIN LIMITED on the NSE today (05 Sep 2026) was ₹2,237.90. This compares to the 52-week high of ₹2,529.50 recorded on 16 Jul 2026. Today's high was -11.53% below the 52-week high.
The intraday low for LUPIN LIMITED on the NSE today was ₹2,100.60. The stock's 52-week low stands at ₹1,900.00, recorded on 28 Oct 2025. Today's low is 10.56% above the 52-week low, indicating the stock is trading well above its yearly lows.
LUPIN LIMITED has delivered 9.68% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹2,529.50 on 16 Jul 2026 and a 52-week low of ₹1,900.00 on 28 Oct 2025. It is currently trading at ₹2,110.00 as of 05 Sep 2026.
LUPIN LIMITED has delivered a 117.12% absolute return over the past 5 years, equivalent to a CAGR of 16.77% per annum. The stock was priced at ₹971.81 in Sep 2021 and has risen to ₹2,110.00 as of 05 Sep 2026. An investment of ₹1,00,000 in LUPIN LIMITED five years ago would be worth ₹2,17,120.00 today.
The all-time high (ATH) for LUPIN LIMITED was ₹2,514.80, recorded on 21 Jul 2026. At the current price of ₹2,110.00, the stock is trading 16.10% below its all-time high. The all-time low recorded was ₹278.53 on 14 Jan 2010.
Yes,LUPIN LIMITED has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 46.00 per share between FY2022 and FY2026, with the most recent dividend of ₹18.00 per share for May 26, with an ex-dividend date of 17 Jul 2026. At the current market price of ₹2,110.00, the trailing dividend yield of LUPIN LIMITED stands at 30.00%.
As of 05 Sep 2026, the share price of LUPIN LIMITED is ₹2,110.00 on the NSE and ₹2,111.00 on the BSE. The stock opened at ₹2,140.10, touched a high of ₹2,237.90 and a low of ₹2,100.60 during today's session.
Over the last 6 months, LUPIN LIMITED has given a return of -8.61%. The stock was priced at ₹2,332.90 on 05 Mar 2026 and has Fallen to ₹2,110.00 as of 05 Sep 2026, a change of ₹222.90 per share.
For Q1 FY27, LUPIN LIMITED reported: Revenue (Net Sales): ₹71719.00 Cr - Up 37.01% year-on-year from ₹52346.00 Cr in Q4 FY26. Net Income (PAT): ₹27146.00 Cr - Up 25.46% year-on-year from ₹21636.90 Cr in Q4 FY26.
